I-AzurRx BioPharma, Inc. ipapasha nini ingxelo kunye nelahleko?
Inzuzo ye-AzurRx BioPharma, Inc. kunye ne-loss statement iyapapashwa kanye nekota, ingxelo yangoku yezimali ye-AzurRx BioPharma, Inc. yashicilelwa ngo-31/03/2021.
Iyintoni inzuzo kwizabelo ze AzurRx BioPharma, Inc.?
Ingeniso ehlawulwayo nganye ngeAzurRx BioPharma, Inc. yayingu--0.14 $ kwingxelo yokugqibela yezemali.
Ngabe i-AzurRx BioPharma, Inc. izakupapasha nini i-profit and loss statement?
Inzuzo elandelayo nenzuzo yokulahleka AzurRx BioPharma, Inc. iya kuba ngo-Isilimela 2024.
AzurRx BioPharma, Inc. ingeniso ngesabelo ngasinye - iimpawu zemali yenkampani kwisayizi yexabiso layo. Umvuzo kwisabelo ngasinye ubalwa ngokungqinelana nefomula: isixa senzuzo yenkampani yethuba lezezimali ngokweengxelo ezisemthethweni zahlulwe ngenani lezabelo kwinkampani. AzurRx BioPharma, Inc. ngesabelo ngasinye ibalwa kwixesha ngalinye lokuphumla kwemali. Inzuzo ye AzurRx BioPharma, Inc. - inzuzo iyonke kwixesha lokunika ingxelo.
|
Inzuzo AzurRx BioPharma, Inc.
Zonke AzurRx BioPharma, Inc. inzuzo sisalathiso. Ayibalulekanga kangako kubanini zabelo babucala. Okubaluleke ngakumbi kubalo lwengeniso ngesabelo ngasinye. Elixabiso lisisiseko sokubala izahlulo kwaye ingaphezulu kwesidingo ngokuqwalaselwa ngabanini zabelo. Umhla wengxelo yenzuzo AzurRx BioPharma, Inc. ibophelelwe kumthetho welizwe wokubhaliswa kwenkampani. Imihla ye AzurRx BioPharma, Inc. iinkcazo zenzuzo yamaxesha asandula ukuboniswa kwitafile kunye negrafu yenkonzo yethu kwi-Intanethi.
|
Inzuzo yekota AzurRx BioPharma, Inc.
Umvuzo ngesabelo ngasinye AzurRx BioPharma, Inc. ibalwa ngokwahlulahlula umvuzo ngenani lezabelo kwinkampani. Umvuzo ngesabelo ngasinye AzurRx BioPharma, Inc. sisalathiso sokuphumla kwemali ethile. Kulula ukuqikelela ukuba ixesha lezezimali liyahambelana nokupapashwa kwengxelo yemali yenzuzo. AzurRx BioPharma, Inc. umvuzo kwisabelo ngasinye sexesha lokunika ingxelo sokugqibela sinokufumaneka kwitafile yethu (umqolo ophezulu) okanye igrafu (ikholamu esekunene). AzurRx BioPharma, Inc. ingeniso yekota yohlalutyo lwemali yingxelo yethutyana yonyaka-mali.
|
|
AZRX umhla wokubika
|
Iintlawulo nge share
Iintlawulo ngezabelo zibalwa ngokuhlula ngeniso engenayo (okanye inzuzo) ngenani lezabelo zenkampani.
|
Utshintsho kunyaka %
|
|
31/03/2021 |
-0.14 USD |
- |
|
31/12/2020 |
-0.31 USD |
- |
|
30/09/2020 |
-0.47 USD |
+176.47% ↑ |
|
30/06/2020 |
-0.17 USD |
-32% ↓ |
|
30/09/2019 |
-0.17 USD |
-20% ↓ |
|
30/06/2019 |
-0.25 USD |
-12.5% ↓ |
|
31/03/2019 |
-0.26 USD |
- |
|
31/12/2018 |
-0.24 USD |
-28% ↓ |
|
30/09/2018 |
-0.15 USD |
-15% ↓ |
|
30/06/2018 |
-0.22 USD |
-11.111% ↓ |
|
31/03/2018 |
-0.29 USD |
-27.778% ↓ |
|
31/12/2017 |
-0.21 USD |
-76.191% ↓ |
|
30/09/2017 |
-0.28 USD |
- |
|
30/06/2017 |
-0.27 USD |
- |
|
31/03/2017 |
-0.29 USD |
- |
|
31/12/2016 |
-0.64 USD |
- |
AzurRx BioPharma, Inc. ingeniso yekota nganye kwisabelo ngasinye yinzuzo eqikelelweyo yenkampani. Banokubaluleka okuphakathi phakathi kwabahlalutyi. Kodwa umvuzo wonyaka ngesabelo ngasinye ubaluleke kakhulu. Inzuzo yekota egqithileyo AzurRx BioPharma, Inc. namhlanje yimali ebhengezwe ngokusemthethweni ngekota yokugqibela. Utshintsho kwingeniso AzurRx BioPharma, Inc. yonyaka lixabiso elibaliweyo lolwazi olongezelelekileyo olubonisa utshintsho lwepesenti yenzuzo ngokuphumla okufanayo kunyaka ophelileyo. Utshintsho ngaphakathi AzurRx BioPharma, Inc. inzuzo yekota ngokuthelekisa kunyaka ophelileyo inokubaluleka kwiinkampani ezineshishini lamaxesha athile. Kodwa olona phawu lubalulekileyo kwinkampani yinkqubela phambili yenzuzo.
Ukulungiselela umbono kunye nohlalutyo, sipapasha utshintsho kwinzuzo njengepesenti. Imbali yenzuzo ye AzurRx BioPharma, Inc. kule minyaka idlulileyo kunye namaxesha okunika ingxelo kukwitheyibhile "Inzuzo yekota". AzurRx BioPharma, Inc. imbali yengeniso yekota iyafumaneka kwi-intanethi kunyaka ngamnye nakwikota kule minyaka ilishumi idlulileyo. AzurRx BioPharma, Inc. i-database yokufumana inzuzo kwi-intanethi yexesha elidlulileyo lihlanganiswa ukusuka kwimithombo esemthethweni eqinisekisiweyo ngalo lonke ixesha.
|
